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INTRODUCTION 
Urinary incontinence occurs in 10-40% of women, affect-
ing more than two hundred million women worldwide. Stress
urinary incontinence is the most common form, accounting
for about 50% of all types of incontinence. Stress urinary in-
continence is the involuntary urination resulting from incre-
ase in stress, where urine leaks without bladder contraction,
and peaks in women aged 45 to 49 yr. Affecting 65% of wo-
men aged 45 to 49, urinary incontinence creates hygienic as
well as social problems (1, 2). 
Depending on the pathophysiology, stress urinary incon-
tinence is divided into anatomic incontinence caused by ure-
thral hypermobility and intrinsic sphincter deficiency (ISD).
Surgical treatments for anatomic incontinence include blad-
der neck suspension performed through the abdomen or va-
gina, or the midurethral sling operation using tape. Surgical
treatments for ISD include sling operation, urethral submu-
cosal injection or creation of an artificial urethral sphincter
using fat tissue, teflon, collagen, or silicon. However, a per-
fect treatment method applicable to all types of incontinence
has not yet been created. 
Stem cells have recently emerged as a new treatment me-
thod for various diseases. Primal undifferentiated cells, stem
cells retain the ability to differentiate into other cell types.
Stem cells are commonly categorized as embryonic or adult,
according to their source. Unlike embryonic stem cells, which
are not easily obtained for clinical application, adult stem
cells can be extracted from human cord blood without harm,
making clinical application relatively easy. Adult stem cells
are present in minute quantities as multipotent cells that
multiply and differentiate in response to damaged tissue or
increased stress. Stem cell therapy for urinary incontinence
has been investigated by others. Yiou and his team reported
that intrinsic satellite cells in striated muscle are useful in
the regeneration of damaged rhabdomyosphincter in mice
(3). Yokoyama and his team reported that injection of mus-
cle-derived progenitor cells (MDPCs) into the mouse ure-
thra yielded better durability than injection of bovine colla-
gen (4). Tracy and his team reported improved sphincter
contractibility induced by injection of allogeneic muscle
derived progenitor cells into the urethra of a mouse with
severed nerves (5). Strasser and his team, who were first to
conduct a human clinical study, performed transurethral in-
jection of autologous muscle-derived stem cells using trans-
urethral ultrasound and reported improved symptoms, a
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Human Cord Blood Stem Cell Therapy for Treatment of Stress 
Urinary Incontinence
Our objective in this study was to evaluate the safety and efficacy of transurethral
cord blood stem cell injection for treatment of stress urinary incontinence in women.
Between July 2005 and July 2006, 39 women underwent transurethral umbilical
cord blood stem cell injection performed by one operator at a single hospital. All
patients had stress urinary incontinence. The patients were evaluated 1, 3, and 12
months postoperatively. No postoperative complications were observed. 28 patients
(77.8%) were more than 50% satisfied according to the Patient’s Satisfaction results
after 1 month, 29 patients (83%) were more than 50% satisfied according to the
Patient’s Satisfaction results after 3 months, and 26 (72.2%) continuously showed
more than 50% improvement after 12 months. Intrinsic sphincter deficiency and
mixed stress incontinency improved in the ten patients evaluated by urodynamic
study. Our results suggest that transurethral umbilical cord blood stem cell injection
is an effective treatment for women with all types of stress urinary incontinence. 
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ter contractibility (6). 
Human cord blood stem cells can transform into other
cell types (transdifferentiation) and are expected to be useful
in the treatment of patients with dysfunction in periurethral
nervous tissue, smooth muscle, striated muscle, urethral mu-
cosa, submucosal connective tissue and various other tissues.
Human cord blood stem cells are expected to yield highly
efficacious treatments. 
Our objective was to evaluate the safety and efficacy of
periurethral cord blood stem cell injection for treatment of
stress urinary incontinence. 
MATERIALS AND METHODS 
This study was carried out from July, 2005 to July, 2006
at the CHA Gangnam Medical Center and School of Medi-
cine, CHA University, with IRB approval. The procedure
was completed on 39 women with urinary incontinence who
had signed informed consent forms. All had previously tried
conservative treatment, and one had been treated with other
surgical method for the disorder, without success. 
All patients were given a Quality-of-life Questionnaire
and Incontinence Impact Questionnaire prior to the proce-
dure. History, physical examination, urine test, urine cul-
ture, general blood test, routine chemistry, cotton-swab test,
urodynamic study, and HLA typing were performed on the
patients. 
The umbilical cord vein was pricked after normal deliv-
ery and then the human umbilical cord blood was collected
in an aseptic collecting bag (National Red Cross, Korea)
containing 23 mL of citrate-phosphate-dextrose-adenine
(CPDA-1) and stored at -70℃. After thawing at 37℃, cord
blood cells were separated into a low-density mononuclear
fraction (<1,077 g/mL) by Ficoll-Paque Plus (GE Health-
care AB, Uppsala, Sweden, http://www.amersham.com). To
briefly summarize the separation method, a small amount
of saline was added to the cord blood and mixed well. Dilut-
ed cord blood was carefully poured into a 15 mL tube which
contained Ficoll (Ficoll:diluted cord blood=3:4). The mix-
ture of diluted cord blood and Ficoll was centrifuged at 1,800
rpm for 30 min and mononuclear cells were carefully drawn
out from the top layer. The cells were stored in 50 mL tubes
with saline, and the withdrawn mononuclear cells were cen-
trifuged three times at 1,800 rpm for 10 min. The cells were
collected afterward and the supernatant was discarded. Saline
(50 mL) was mixed with the remaining cell pellet and the
process of centrifuging at 1,000 rpm for 10 min was repeat-
ed twice. The cell pellet was resuspended with 50 mL saline,
and 10 mL was removed. The cells were then counted. 
All parts of the transurethral umbilical cord blood stem
cell injection were performed by one operator. Antibiotic
was given to the patient prior to periurethral umbilical cord
blood stem cell (UCBSC) injection. After the vagina and
perineum were sterilized, local anesthesia was given in the
vicinity of the urethra in the 4 and 8 o’clock positions with
1% lidocaine. Using a 30° 26 French cystoscope, the vesico-
urethral junction was checked visually. Stem cells removed
from human cord blood were verified in the HLA test, and
HUCB mononuclear cell suspension in saline solution (mean,
4.3±1.9×10
8 cells per 2 mL) were injected into the ure-
thra under cystoscope in the 4 and 8 o’clock positions. Two
injections per patient (1 mL each) were performed in sub-
mucosal area of the proximal-urethra. Injection continued
until the urethral mucosa was completely closed, while the
inflation of urethra mucosa was observed through the cysto-
scope. The patient was released the day of the procedure.
Patients were informed to immediately visit the clinic in
case of any postoperative complications. As follow-up, phys-
ical examination and liver function tests were performed on
a weekly basis for the following month.
Outcomes were evaluated by comparing patients’ voiding
diaries and perceptions. To compare patients’ perceptions, the
Patient Satisfaction Test was performed 1 month, 3 months,
and 12 months after the procedure. A 3-month postopera-
tive urodynamic study was also used to monitor the objec-
tive improvement of urinary incontinence following peri-
urethral UCBSC injection. A urodynamic study was conduct-
ed on ten patients who had a MUCP result of less than 30
cmH2O before the stem cell transplantation 3 months after
the procedure. Individual comparisons were made using Stu-
dent’s t-test. A P-value of less than 0.05 was accepted as sig-
nificant.
RESULTS 
Mean age of the 39 patients treated in the study was 51.5
±7.6 yr. All patients had stress urinary incontinence; 22 had
urethral hypermobility, eight had intrinsic sphincter defi-
ciency, and nine had mixed stress urinary incontinence. One
of the patients had previously undergone a surgical method
to treat incontinence (Table 1). 
Periurethral UCBSC injection took 15 min. Two patients
stopped the injection due to pain during the procedure, but
were not included in the study. None of the cases had void-
ing dysfunction, urinary retention, urinary tract infection or
graft versus host disease (GVHD) resulting from the proce-
dure (Table 2). 
The mean follow-up was 13.0±2.7 months. Three patients
discontinued the 1 month postoperative Patient Satisfaction
Test. 28 (77.8%) showed more than 50% improvement, and
eight (22.2%) reported no improvement in the 1-month post-
operative Patient Satisfaction Test. In the 3-month postop-
erative Patient Satisfaction Test, 29 (80.5%) continuously
showed more than 50% improvement. Finally, In the 12-
month postoperative Patient Satisfaction Test, 26 (72.2%)
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In addition, a 3-month postoperative urodynamic study con-
ducted on five patients with stress urinary incontinence due
to ISD and five patients with mixed stress urinary inconti-
nence verified that in all ten patients the maximal urethral
closing pressure (MUCP) values were increased by more than
30 cmH2O (Table 4). The MUCP values were significantly
improved in the ISD and mixed stress urinary incontinence
patients after 3 months. 
DISCUSSION
Recently, stem cell therapy has been tried for urinary in-
continence under the concept that urinary incontinence is
essentially a degenerative disease, so stem cell may play a
role in regenerating the damaged sphincter. Various types of
tissue have been used as the source of stem cells for the treat-
ment of urinary incontinence. Previous attempts to treat in-
continence with stem cells have not been completely success-
ful. First, harvesting stem cells from the aged patient’s own
muscle is advantageous since rejection complications are
minimized. But unfortunately, the restoration efficiency of
stem cells decreases with age (7). Renault, Thornell and their
team reported that the restoration efficiency of stem cells in
skeletal muscle declines in direct proportion with age (4-6%
vs. 1-2%) (8,9). Jejurikar and his team reported that stem cell
growth and transference also decrease with age (10). Thus,
the therapeutic efficacy of transplanted stem cells obtained
from the patient’s muscle is poor. Second, taking muscle from
the patient’s arm is an invasive procedure associated with
complications of bleeding or infection.
Use of human cord blood overcomes these problems. Glu-
ckman and his team have successfully conducted cord blood
transplantation (CBT) procedures since 1988 (11). It also
has been investigated in many animal models of various de-
generative diseases, such as spinal cord injury model and
cerebral ischemia model, with some promising results (12-
14). CBT has a low risk of causing GVHD and viral con-
tamination, requires less stringent HLA matching and is
easily performed. Furthermore, cord blood stem cells are
obtained from a large source of donors.
As far as we know, this is the first use of human cord blood
stem cells for treatment of urinary incontinence. Periurethral
UCBSC injection is a very short, minimally invasive outpa-
tient procedure that is not associated with complications.
Human cord blood stem cell therapy improved different
types of stress urinary incontinence 3 months after the pro-
cedure in 80% of our study patients. A urodynamic study
conducted on ten patients who had a MUCP result of less
than 30 cmH2O before the stem cell transplantation showed
improved function of greater than 30 cmH2O in MUCP 3
months after the procedure. 
Unfortunately, the number of patients studied was too
small to allow comparison of therapeutic efficacy for the dif-
ferent types of stress urinary incontinence. Long term follow-
up of more than a year and investigation into the mechanism
of stem cell therapy are goals for our next study. 
In conclusion, periurethral injection of human cord blood
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Characteristics Patients (n=39)
Mean age (yr) 51.0±7.6 (36-68)
Mean parity 2.3±0.8 (1-4)
Type of stress urinary incontinence 
Urethral hypermobility (Q-tip test ≥30°) group 22 (56.4%)
ISD (MUCP ≤30 cmH2O) group 8 (20.5%)
Mixed group 9 (23.1%)
Previous incontinence surgery 1 (2.6%)
Mean number of injected cells 4.3±1.9×10
8
Loss of follow up 3 (7.7%)
Table 1. Characteristics of patients undergoing transurethral
UCBSC injection
UCBSC, umbilical cord blood stem cell; MUCP, maximal urethral clos-
ing pressure.
Complications Number (%)
Failure of procedure 
Interruption due to pain 2 (4.9%)
Postoperative complication
Voiding difficulty 0
Urinary retention 0
Urinary tract infection 0
GVHD 0
Table 2. Complications of the transurethral UCBSC injection
GVHD, graft versus host disease.
Outcomes 1 mo after 3 mo after 6 mo after 12 mo after
Cure (≥90%) 6 (16.7%) 8 (22.2%) 12 (33.3%) 13 (36.1%)
Improvement 22 (61.1%) 21 (58.3%) 14 (38.9%) 13 (36.1%)
Marked (75-90%) 8 15 9 7
Slightly (50-75%) 14 6 5 6
Failure (≤50%) 8 (22.2%) 7 (19.4%) 10 (27.8%) 10 (27.8%)
Total 36 36 36 36
Table 3. Postoperative subjective cure rates-Patient Satisfaction
36/39 patients were checked.
Postoperative MUCP Preoperative MUCP
30 cmH2O <30 cmH2O ≥30 cmH2O
ISD group  5 (mean 25.4±5.6) 0 5 (mean 56.0±11.5)
Mixed group  5 (mean 27.0±6.7) 0 5 (mean 44.0±8.0)
Total  10 (mean 20.3±5.9) 0 10 (mean 45.0±9.7)
Table 4. Postoperative objective cure rates-Urodynamic study
(except for urethral hypermobility group)
MUCP, maximal urethral closing pressure; ISD, intrinsic sphincter defi-
ciency; 10/19 patients were checked.stem cells was effective, at least for the short term, with a
lower incidence of surgery related complications compared
to previous surgical methods.
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